- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Novartis CEO joins board of "responsible" AI firm Anthropic | ||
| Mi | Scientists issue call to arms over antifungal resistance | ||
| Mi | Daiichi exits OTC, with $1.55bn unit sale to Suntory | ||
| Mi | Parkinson's charity partners Biognosys on biomarker project | ||
| Mi | Amazon launches its AI drug discovery platform | ||
| Mi | FDA seeks safety data for Lilly's oral GLP-1 Foundayo | ||
| Di | FDA renews criticism of trial sponsors over transparency | ||
| Di | Novo Nordisk partners OpenAI on R&D "transformation" | ||
| Di | Travere claims first FDA OK in rare kidney disease FSGS | ||
| Di | Revolution rockets on strong pancreatic cancer data | ||
| Di | Alamar, Hemab, Kailera, and Seaport advance IPOs | ||
| Mo | IDEAYA/Servier PKC drug aces uveal melanoma trial | ||
| Mo | AI could spare bowel cancer patients from unneeded treatment | ||
| Mo | NICE update doubles eligible patients for AZ's Lokelma | ||
| Mo | Data backs GSK's ovarian cancer blockbuster hopes | ||
| Mo | FDA hands another rejection to Replimune's melanoma therapy | ||
| Fr | Senju launches first-in-class dry eye disease drug in Japan | ||
| Fr | Diagnostics lag is holding back new therapies, says study | ||
| Fr | Chinese trial backs base-editing drug for thalassaemia | ||
| Fr | Roche places a $1bn bet on C4T degrader-antibody conjugates | ||
| Fr | Boehringer transfers schizophrenia DTx selling rights to Click | ||
| 09.04. | Pulmonary fibrosis drug developer Avalyn files IPO | ||
| 09.04. | NHS risks missing out on independent prescriber benefits | ||
| 09.04. | AbbVie tries a new approach in 340B programme battle | ||
| 09.04. | 23andMe study explains variable results with obesity drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.